MX2017013902A - Agonistas del receptor 5-ht2c y composiciones y metodos de uso. - Google Patents
Agonistas del receptor 5-ht2c y composiciones y metodos de uso.Info
- Publication number
- MX2017013902A MX2017013902A MX2017013902A MX2017013902A MX2017013902A MX 2017013902 A MX2017013902 A MX 2017013902A MX 2017013902 A MX2017013902 A MX 2017013902A MX 2017013902 A MX2017013902 A MX 2017013902A MX 2017013902 A MX2017013902 A MX 2017013902A
- Authority
- MX
- Mexico
- Prior art keywords
- tobacco
- individual
- disorders
- smoking
- nicotine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 title 1
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 208000025569 Tobacco Use disease Diseases 0.000 abstract 5
- 230000000391 smoking effect Effects 0.000 abstract 5
- 241000208125 Nicotiana Species 0.000 abstract 4
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract 4
- 206010057852 Nicotine dependence Diseases 0.000 abstract 4
- 230000004584 weight gain Effects 0.000 abstract 4
- 235000019786 weight gain Nutrition 0.000 abstract 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229960002715 nicotine Drugs 0.000 abstract 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 3
- 208000016285 Movement disease Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 230000000561 anti-psychotic effect Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 208000019116 sleep disease Diseases 0.000 abstract 2
- 230000000153 supplemental effect Effects 0.000 abstract 2
- 235000019505 tobacco product Nutrition 0.000 abstract 2
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000010228 Erectile Dysfunction Diseases 0.000 abstract 1
- 208000001613 Gambling Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000030990 Impulse-control disease Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 206010057342 Onychophagia Diseases 0.000 abstract 1
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 206010034158 Pathological gambling Diseases 0.000 abstract 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 206010046543 Urinary incontinence Diseases 0.000 abstract 1
- 201000007930 alcohol dependence Diseases 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 230000036186 satiety Effects 0.000 abstract 1
- 235000019627 satiety Nutrition 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 230000007958 sleep Effects 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
- 208000022925 sleep disturbance Diseases 0.000 abstract 1
- 230000037322 slow-wave sleep Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 238000004260 weight control Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En algunas modalidades se proveen compuestos en la presente solicitud. En algunas modalidades también se proveen métodos para control de peso, inducir saciedad, y disminuir la ingesta de alimentos, y para prevenir y tratar obesidad, aumento de peso inducido por antipsicótico, diabetes tipo 2, síndrome de Prader-Willi, dependencia del tabaco/nicotina, drogadicción, alcoholismo, juego patológico, síndrome de deficiencia de recompensa, y adicción al sexo, trastornos del espectro obsesivo-compulsivo y trastornos del control de los impulsos (incluyendo el hábito de morderse las uñas y onicofagia), trastornos del sueño (incluyendo insomnio, arquitectura del sueño fragmentada, y alteraciones del sueño de onda lenta), incontinencia urinaria, trastornos psiquiátricos (incluyendo esquizofrenia, anorexia nerviosa, y bulimia nerviosa), enfermedad de Alzheimer, disfunción sexual, disfunción eréctil, epilepsia, trastornos del movimiento (incluyendo parkinsonismo y trastorno del movimiento inducido por antipsicótico), hipertensión, dislipidemia, enfermedad de hígado graso no alcohólica, enfermedad renal relacionada con la obesidad, y apnea del sueño. En algunas modalidades también se proveen composiciones que comprenden un compuesto en la presente solicitud, opcionalmente en combinación con un agente suplementario, y métodos para reducir la frecuencia de fumar tabaco en un individuo que intenta reducir la frecuencia de fumar tabaco; ayudar en la cesación o disminución del uso de un producto de tabaco en un individuo que intenta cesar o disminuir el uso de un producto de tabaco; ayudar a dejar de fumar y prevenir el aumento de peso asociado; controlar el aumento de peso asociado con dejar de fumar por un individuo que intenta dejar de fumar tabaco; reducir el aumento de peso asociado con dejar de fumar por un individuo que intenta dejar de fumar tabaco; tratar la dependencia, adicción y/o abstinencia de nicotina en un individuo que intenta tratar la dependencia, adicción y/o abstinencia de nicotina; o reducir la probabilidad de recaer en el uso de nicotina por un individuo que intenta dejar de utilizar nicotina que comprende administrar un compuesto de la presente solicitud, opcionalmente en combinación con un agente suplementario.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153082P | 2015-04-27 | 2015-04-27 | |
| PCT/US2016/029308 WO2016176177A1 (en) | 2015-04-27 | 2016-04-26 | 5-ht2c receptor agonists and compositions and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017013902A true MX2017013902A (es) | 2018-03-16 |
| MX373319B MX373319B (es) | 2020-06-13 |
Family
ID=55949111
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013902A MX373319B (es) | 2015-04-27 | 2016-04-26 | Derivados de hexahidro-[1-4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor. |
| MX2020005898A MX2020005898A (es) | 2015-04-27 | 2017-10-27 | Derivados de hexahidro-[1,4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020005898A MX2020005898A (es) | 2015-04-27 | 2017-10-27 | Derivados de hexahidro-[1,4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10392390B2 (es) |
| EP (1) | EP3288946B1 (es) |
| JP (1) | JP6675688B2 (es) |
| KR (1) | KR102275505B1 (es) |
| CN (1) | CN107873030B (es) |
| AU (1) | AU2016255009B2 (es) |
| BR (1) | BR112017023088B1 (es) |
| CA (1) | CA3002544C (es) |
| DK (1) | DK3288946T3 (es) |
| EA (1) | EA034446B1 (es) |
| ES (1) | ES2757922T3 (es) |
| HK (1) | HK1244005B (es) |
| HR (1) | HRP20192044T1 (es) |
| HU (1) | HUE047169T2 (es) |
| IL (1) | IL255171A0 (es) |
| MX (2) | MX373319B (es) |
| PT (1) | PT3288946T (es) |
| WO (1) | WO2016176177A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| JPWO2019131902A1 (ja) | 2017-12-27 | 2020-12-10 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
| CN118384147A (zh) | 2018-01-30 | 2024-07-26 | 爱普宁公司(特拉华) | 用于治疗睡眠呼吸暂停的方法和组合物 |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| KR20210125507A (ko) * | 2019-02-08 | 2021-10-18 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 수면성 무호흡의 치료 방법 및 조성물 |
| WO2020212951A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin |
| US12205686B2 (en) * | 2020-02-27 | 2025-01-21 | The Cleveland Clinic Foundation | Identifying patients for intensive hyperglycemia management |
| US20250073206A1 (en) * | 2021-10-29 | 2025-03-06 | Sensorium Therapeutics, Inc. | Solid forms of mesembrine and therapeutic uses thereof |
| EP4444298A4 (en) * | 2021-12-10 | 2025-06-04 | GATC Health Corp | Methods of treating addiction and neurological disorders |
| US20230293546A1 (en) | 2022-03-10 | 2023-09-21 | Arena Pharmaceuticals, Inc. | Methods of treatment |
| CN114965250B (zh) * | 2022-05-19 | 2025-02-14 | 道生天合材料科技(上海)股份有限公司 | 胶粘剂储存期的预测方法 |
| WO2023225773A1 (en) * | 2022-05-23 | 2023-11-30 | Sensorium Therapeutics, Inc. | Solid forms of mesembrine and therapeutic uses thereof |
| AU2023406232A1 (en) * | 2022-12-02 | 2025-05-22 | Arena Pharmaceuticals, Inc. | Methods of treatment |
| WO2024173626A1 (en) * | 2023-02-17 | 2024-08-22 | Caamtech, Inc. | 2-(2,5-diethoxy-4-(ethylthio)phenyl)ethane-1-aminium chloride |
| IL323075A (en) * | 2023-03-02 | 2025-10-01 | Alexander Shulgin Res Institute Inc | Phenylalkylamine drugs |
| TW202529748A (zh) * | 2023-10-11 | 2025-08-01 | 義大利帕多瓦大學 | 使用賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）及賽洛辛（ｐｓｉｌｏｃｉｎ）衍生物之治療方法 |
| WO2026025075A1 (en) | 2024-07-26 | 2026-01-29 | Arena Pharmaceuticals, Inc. | Bexicaserin for use in the treatment and/or prevention of epileptic disorders in a child patient |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3642822A (en) * | 1969-11-03 | 1972-02-15 | Upjohn Co | Hexahydropyrrolobenzodiazepines |
| US4597961A (en) | 1985-01-23 | 1986-07-01 | Etscorn Frank T | Transcutaneous application of nicotine |
| US4920989A (en) | 1985-04-25 | 1990-05-01 | Regents Of The University Of California | Method and apparatus for aiding in the reduction of incidence of tobacco smoking |
| IL86170A (en) | 1987-05-01 | 1992-12-01 | Elan Transdermal Ltd | Preparations and compositions comprising nicotine for percutaneous administration |
| US5004610A (en) | 1988-06-14 | 1991-04-02 | Alza Corporation | Subsaturated nicotine transdermal therapeutic system |
| AU1919592A (en) | 1991-04-16 | 1992-11-17 | National Institutes Of Health | Method of treating trichotillomania and onychophagia |
| AU2002227170A1 (en) * | 2000-11-03 | 2002-05-15 | Wyeth | Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives |
| EP1330457B1 (en) * | 2000-11-03 | 2004-10-20 | Wyeth | Cyclopenta[b][1,4] diazepino[6,7,1-hi]indoles as 5ht2c antagonists |
| AU2003228485A1 (en) | 2002-04-12 | 2003-10-27 | The University Of Chicago | Farnesoid x-activated receptor agonists |
| TW200307540A (en) * | 2002-04-25 | 2003-12-16 | Wyeth Corp | [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents |
| JP4782003B2 (ja) * | 2003-06-17 | 2011-09-28 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ５ｈｔ２ｃレセプター関連疾患の処置に有用なベンズアゼピン誘導体 |
| BRPI0709129A2 (pt) * | 2006-03-24 | 2011-06-28 | Wyeth Corp | combinações terapêuticas para o tratamento ou prevenção de transtornos psicóticos |
| US9556200B2 (en) * | 2012-03-06 | 2017-01-31 | Takeda Pharmaceutical Company Limited | Tricyclic compound |
| WO2014041131A1 (en) * | 2012-09-14 | 2014-03-20 | AbbVie Deutschland GmbH & Co. KG | Tricyclic quinoline and quinoxaline derivatives |
| WO2015066344A1 (en) * | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
-
2016
- 2016-04-26 WO PCT/US2016/029308 patent/WO2016176177A1/en not_active Ceased
- 2016-04-26 JP JP2017555768A patent/JP6675688B2/ja active Active
- 2016-04-26 ES ES16721320T patent/ES2757922T3/es active Active
- 2016-04-26 MX MX2017013902A patent/MX373319B/es active IP Right Grant
- 2016-04-26 EP EP16721320.6A patent/EP3288946B1/en active Active
- 2016-04-26 AU AU2016255009A patent/AU2016255009B2/en active Active
- 2016-04-26 HR HRP20192044TT patent/HRP20192044T1/hr unknown
- 2016-04-26 CA CA3002544A patent/CA3002544C/en active Active
- 2016-04-26 HU HUE16721320A patent/HUE047169T2/hu unknown
- 2016-04-26 DK DK16721320T patent/DK3288946T3/da active
- 2016-04-26 HK HK18103485.6A patent/HK1244005B/en unknown
- 2016-04-26 KR KR1020177033892A patent/KR102275505B1/ko active Active
- 2016-04-26 EA EA201792356A patent/EA034446B1/ru not_active IP Right Cessation
- 2016-04-26 BR BR112017023088-7A patent/BR112017023088B1/pt active IP Right Grant
- 2016-04-26 PT PT167213206T patent/PT3288946T/pt unknown
- 2016-04-26 US US15/567,116 patent/US10392390B2/en active Active
- 2016-04-26 CN CN201680037275.XA patent/CN107873030B/zh active Active
-
2017
- 2017-10-22 IL IL255171A patent/IL255171A0/en active IP Right Grant
- 2017-10-27 MX MX2020005898A patent/MX2020005898A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN107873030A (zh) | 2018-04-03 |
| CA3002544C (en) | 2024-03-05 |
| MX373319B (es) | 2020-06-13 |
| HRP20192044T1 (hr) | 2020-02-07 |
| NZ737412A (en) | 2021-06-25 |
| DK3288946T3 (da) | 2019-11-25 |
| PT3288946T (pt) | 2019-11-27 |
| EP3288946B1 (en) | 2019-08-21 |
| WO2016176177A1 (en) | 2016-11-03 |
| MX2020005898A (es) | 2020-08-13 |
| BR112017023088A2 (pt) | 2018-07-10 |
| EA034446B1 (ru) | 2020-02-10 |
| ES2757922T3 (es) | 2020-04-30 |
| EA201792356A1 (ru) | 2018-05-31 |
| CA3002544A1 (en) | 2016-11-03 |
| JP6675688B2 (ja) | 2020-04-01 |
| KR20170140317A (ko) | 2017-12-20 |
| AU2016255009A1 (en) | 2017-12-14 |
| JP2018519251A (ja) | 2018-07-19 |
| HUE047169T2 (hu) | 2020-04-28 |
| BR112017023088B1 (pt) | 2023-10-03 |
| EP3288946A1 (en) | 2018-03-07 |
| HK1244005B (en) | 2020-04-17 |
| US20180186797A1 (en) | 2018-07-05 |
| AU2016255009B2 (en) | 2020-10-08 |
| KR102275505B1 (ko) | 2021-07-08 |
| CN107873030B (zh) | 2021-03-19 |
| US10392390B2 (en) | 2019-08-27 |
| IL255171A0 (en) | 2017-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013902A (es) | Agonistas del receptor 5-ht2c y composiciones y metodos de uso. | |
| MX2018001380A (es) | Agonistas del receptor 5-ht2c y composiciones y metodos de uso. | |
| NZ750469A (en) | 5-ht2c receptor agonists and compositions and methods of use | |
| MX2020002060A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos. | |
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| EA201591290A3 (ru) | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| MX2022007012A (es) | Uso de un agonista doble del receptor de glp-1/glucagon de larga accion para el tratamiento de la enfermedad de higado graso no alcoholico. | |
| GEP20257788B (en) | Methods and compositions for treating sleep apnea | |
| MX2020003920A (es) | Tratamiento de trastornos metabolicos en animales caninos. | |
| EA201201201A1 (ru) | Новые ингибиторы rock | |
| MX384234B (es) | Uso de pridopidina para el tratamiento de enfermedad de huntington. | |
| MX2025007820A (es) | Anticuerpo agonista del receptor de leptina para usarse en el tratamiento de una disfuncion metabolica o hipoleptinemia | |
| JOP20190008A1 (ar) | علاج ومنع اضطرابات النوم | |
| PH12016502394A1 (en) | 1, 3, 4-thiadiazole compounds and their use in treating cancer | |
| TN2017000158A1 (en) | Carbazole derivatives | |
| AR098271A1 (es) | Agonistas del receptor 5-ht₂c | |
| RU2020119597A (ru) | Композиция для лечения пациента с респираторным заболеванием, обусловленным хроническим воспалением, способ получения и применение указанной композиции | |
| JOP20200046A1 (ar) | طرق لعلاج أمراض مرتبطة بـtnf? | |
| 真橋尚吾 et al. | Cervical cord injury without cervical spine injury discovered by an anterior approach we developed: two case reports. | |
| Wardle | All in the mind | |
| EA201891690A1 (ru) | Агонист fxr, представляющий собой производное стероидов | |
| UA106849C2 (uk) | Спосіб корекції порушень пружно-еластичних властивостей артерій еластичного типу у хворих на ішемічну хворобу та гіпертонічну хворобу серця |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |